The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan

Author(s):
Slingerland, M.; Gelderblom, H.
Published
2012
Publication type
Article / Letter to editor
CampthotecinColorectal cancerPhase IIBAY 56-3722
Date issued
2012-06-30
Language
English
Is part of
Investigational New Drugs (2012), Vol. 30, no. 3, p. 1208-1210
hdl
1887/97535
doi
10.1007/s10637-011-9679-4